1. Home
  2. HXHX vs APM Comparison

HXHX vs APM Comparison

Compare HXHX & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HXHX

Haoxin Holdings Limited Class A Ordinary Shares

HOLD

Current Price

$0.86

Market Cap

6.2M

Sector

Industrials

ML Signal

HOLD

Logo Aptorum Group Limited

APM

Aptorum Group Limited

HOLD

Current Price

$0.86

Market Cap

7.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HXHX
APM
Founded
2003
2010
Country
China
United Kingdom
Employees
85
N/A
Industry
Trucking Freight/Courier Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.2M
7.3M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
HXHX
APM
Price
$0.86
$0.86
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.5M
219.0K
Earning Date
05-20-2026
03-31-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.96
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.33
$0.65
52 Week High
$1.84
$4.47

Technical Indicators

Market Signals
Indicator
HXHX
APM
Relative Strength Index (RSI) 72.66 45.60
Support Level $0.41 $0.74
Resistance Level $0.92 $0.98
Average True Range (ATR) 0.13 0.17
MACD 0.03 0.01
Stochastic Oscillator 67.90 12.59

Price Performance

Historical Comparison
HXHX
APM

About HXHX Haoxin Holdings Limited Class A Ordinary Shares

Haoxin Holdings Ltd is engaged in the logistics industry, including container provider of temperature-controlled truckload service and urban delivery services in China, freight forwarding, cold chain transportation and other businesses. The types of goods involved are all kinds of new energy materials that require low temperature, heat preservation, and constant temperature, electronic products, medicines, meat, fruits, vegetables and others.

About APM Aptorum Group Limited

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.

Share on Social Networks: